Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pilot study of low-dose interleukin-11 in patients with bone marrow failure
Autore:
Kurzrock, R; Cortes, J; Thomas, DA; Jeha, S; Pilat, S; Talpaz, M;
Indirizzi:
Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030USA Univ Texas Houston TX USA 77030 pt Bioimmunotherapy, Houston, TX 77030USA Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 Ctr, Dept Leukemia, Houston, TX 77030 USA Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 c Ctr, Dept Pediat, Houston, TX 77030 USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 21, volume: 19, anno: 2001,
pagine: 4165 - 4172
SICI:
0732-183X(20011101)19:21<4165:PSOLII>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; RECOMBINANT-HUMAN-ERYTHROPOIETIN; PHASE-I TRIAL; MYELODYSPLASTIC SYNDROMES; APLASTIC-ANEMIA; GM-CSF; THROMBOCYTOPENIA; MULTICENTER; I/II; TRANSPLANTATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
52
Recensione:
Indirizzi per estratti:
Indirizzo: Kurzrock, R Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, 1515 Holcombe Blvd,Box 422, Houston, TX 77030 USA Univ Texas 1515 Holcombe Blvd,Box 422 Houston TX USA 77030 USA
Citazione:
R. Kurzrock et al., "Pilot study of low-dose interleukin-11 in patients with bone marrow failure", J CL ONCOL, 19(21), 2001, pp. 4165-4172

Abstract

Purpose: Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates postchemotherapy thrombocytopenia at doses of 50 mug/kg/d subcutaneously. Very little is known about the activity of IL-11 in patients with bone marrow failure states. Patients and Methods: Our preliminary experience with IL-11 at doses of 50mug/kg/d suggested that patients with bone marrow failure developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We, therefore, initiated a study of low-dose IL-11 (starting dose, 10 mug/kg/d). Results: Sixteen patients were assessable for response. Six patients had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six (38%) of 16 patients showed a platelet response to IL-11, and two had a multilineage response (to IL-11 alone, n = 1, to IL-11 plus G-CSF and erythropoietin, n = 1). The median increase in peak platelet counts was 95 x 10(9)/L above baseline in the responders (range, increase of 55 x 10(9)/L to130 x 10(9)/L. above baseline). Responders included five of 11 patients with myelodysplasia and one of four patients with aplastic anemia. Response durations were 12,13,14+, 25, 30, and 30+ weeks. Side effects of IL-11 were mild (peripheral edema, n = 7, conjunctival injection, n = 7, myalgic, n 1;all grade 1). Seven patients had no side effects. Conclusion: Our pilot study suggests that administration of low-dose IL-11(10 mug/kg/d) can raise platelet counts without significant toxicity in selected thrombocytopenic patients with bone marrow failure. (C) 2001 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 10:57:09